Hanson & Doremus Investment Management Arrowhead Pharmaceuticals, Inc. Transaction History
Hanson & Doremus Investment Management
- $580 Million
- Q1 2024
A detailed history of Hanson & Doremus Investment Management transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Hanson & Doremus Investment Management holds 320 shares of ARWR stock, worth $8,022. This represents 0.0% of its overall portfolio holdings.
Number of Shares
320
Previous 320
-0.0%
Holding current value
$8,022
Previous $9,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ARWR
# of Institutions
296Shares Held
88.5MCall Options Held
905KPut Options Held
387K-
Black Rock Inc. New York, NY15.3MShares$385 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.4MShares$311 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.56MShares$214 Million2.95% of portfolio
-
State Street Corp Boston, MA6.56MShares$164 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.14MShares$104 Million2.38% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.65B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...